Exhibit 99.4

Pro Forma Condensed Combined Balance Sheet and Statement of Operations for Streamline Health Solutions, Inc. and Meta Technology, Inc. as of July 31, 2012 and January 31, 2012

The following unaudited pro forma condensed financial statements are presented to illustrate the effect on the historical financial position and operating results as a result of the acquisition of Meta Health Technology, Inc. (“Meta”) by Streamline Health Solutions, Inc. (“the Company”). The unaudited pro forma condensed financial statements also give effect to events that are directly attributable to the acquisition and are factually supportable, including the debt financing transaction with Fifth Third Bank, used to finance the acquisition.

The following two unaudited pro forma condensed combined statements of operations are presented using the Company’s results for the year ended January 31, 2012 and the six months ended July 31, 2012, and Meta’s results for the year ended December 31, 2011 and the six months ended June 30, 2012. Interpoint Partners, LLC operations from December 7, 2011 to January 31, 2012 are reflected in the historical column of Streamline Health Solutions, Inc. The unaudited condensed combined pro forma statements of operations present the pro forma adjustments as if the acquisition had occurred on February 1, 2011 and the unaudited pro forma condensed combined balance sheet is presented on a pro forma basis as to give effect to the completed acquisition as if it had occurred on July 31, 2012.

The following unaudited pro forma condensed combined balance sheet is presented using the Company’s condition as of July 31, 2012 and Meta’s as of June 30, 2012. There have been no unusual events or transactions related to Meta for the one month period ended July 31, 2012 which would require disclosure in the pro forma condensed combined financial statements.

The pro forma financial statements have been prepared using the acquisition method of accounting under Generally Accepted Accounting Principles, which is subject to change and interpretation. Streamline Health Solutions, Inc. has been treated as the acquirer in the completed acquisition for accounting purposes. Assumptions and estimates underlying the pro forma adjustments are described in the accompanying notes, which should be read in conjunction with the pro forma condensed combined financial statements.

Acquisition accounting is dependent upon certain valuations and other studies that have not yet been completed. Accordingly, the pro forma adjustments are preliminary and have been made solely for the purpose of preparing the pro forma financial statements and are based on preliminary information available at the time of the preparation of this Form 8-K/A. Differences between these preliminary estimates and the final acquisition accounting could occur and these differences could have a material impact on the pro forma financial statements and the combined company’s future results of operations and financial position.

The pro forma financial statements do not reflect any cost savings or other synergies that the combined company may achieve as a result of the completed acquisition or the costs to integrate the operations of the Company and Meta or the cost necessary to achieve these cost savings and other synergies. The effects of the foregoing items could, individually or in the aggregate, materially impact the pro forma financial statements.

The following unaudited pro forma condensed combined financial statements, or the “pro forma financial statements” were derived from and should be read in conjunction with:

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

As of July 31, 2012

See Accompanying Introduction and Notes to Unaudited Pro Forma Condensed Combined Balance Sheet

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

As of July 31, 2012

Description of Transaction

On August 16, 2012, the Company closed the acquisition of substantially all of the outstanding stock of New York City—based Meta Health Technology, Inc. The Company paid a total purchase price of $15 million, consisting of $14.4 million in cash and the issuance of shares of the Company's common stock having an agreed upon value of $1.5 million. As of August 30, 2012, the Company has acquired the remaining shares of Meta Health Technology, Inc. In conjunction with the acquisition, on August 16, 2012, the Company amended its previous Subordinated Credit Agreement and Senior Credit Agreement with Fifth Third Bank, whereby Fifth Third Bank provided the Company with a $5 million senior term loan and a $9 million subordinated term loan, a portion of which was used to refinance the previously outstanding $4.1 million subordinated term loan. The proceeds of these loans were used to finance the cash portion of the acquisition purchase price and to cover any additional operation costs as a result of the acquisition.

In a separate transaction, on August 16, 2012, the Company completed a $12 million debt and equity financing with affiliated funds and accounts of Greenwich-based Great Point Partners, LLC and Atlanta-based Noro-Moseley Partners VI, L.P and another private investor. The equity investment consisted of the Company issuing 2,416,785 shares of a new Series A 0% Convertible Preferred Stock at $3.00 per share ("the Preferred Stock"), warrants exercisable for up to 1,200,000 shares of the Company's common stock at an exercise price of $3.99 per share ("the Warrants") and Convertible Subordinated Notes in the aggregate principal amount of $5,699,577, which, upon stockholder approval, convert into 1,583,220 shares of the Preferred Stock. The Warrants may be exercised at any time during the period beginning on February 17, 2013 until 5 years from such initial exercise date.

Basis of Presentation

The pro forma financial statements were prepared using the acquisition method of accounting in accordance with Financial Accounting Standards Board's Accounting Standards Codification (ASC) 805, Business Combinations, and uses the fair value concepts defined in ASC 820, Fair Value Measurements and Disclosures. ASC 805 requires, among other things, that most assets acquired and liabilities assumed be recognized at their fair value as of the date the acquisition was completed. ASC 820 defines the term "fair value" and sets forth the valuation requirements for any asset or liability measured at fair value, expands related disclosure requirements and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined in ASC 820 as "the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." This is an exit price concept for valuation of the asset or liability. In addition, market participants are assumed to be buyers and sellers in the principal (or the most advantageous) market for the asset or liability. Fair value measurements for an asset assume the highest and best use by these market participants. As a result of these standards, Streamline Health Solutions, Inc. may be required to record assets which are not intended to be used or sold and/or to value assets at fair value measures that do not reflect the Company's intended use of those assets. Many of these fair value measurements can be highly subjective and it is also possible that other professionals, applying reasonable judgement to the same facts and circumstances, could develop and support a range of alternative estimated amounts.

Under ASC 805, acqusition-related transaction costs (e.g., advisory, legal, valuation, other professional fees) and certain acquisition-related restructuring charges impacting the target company are not included as a component of consideration transferred but are accounted for as expenses in the periods in which the costs are incurred. Total advisory, legal, regulatory and valuation costs expected to be incurred by the Company are estimated to be approximately $621,214. $545,148 of these amounts have been paid or accrued in the six months ended July 31, 2012, and therefore, the remaining amount of these costs for the Company are reflected in the unaudited pro forma condensed combined balance sheet as an accrual and a reduction to retained earnings. In addition, $590,583 of debt re-financing costs will be capitalized and will be amortized over the life of the debt and equity financing of 24 months. The $1,098,309 transaction costs related to the debt and equity financing were allocated between the liability and equity components based on the proportion that each component represents of total proceeds of issuance.

The number of shares of common stock issued are based on the closing price as of August 16, 2012 of $3.82 per share.

Marketable securities were liquidized and distributed to shareholders prior to the acquisition.

Number of shares issued was 393,086.

The following reconciles the net assets of Meta Health at June 30, 2012, to the amount acquired in the completed acquisition:

As part of the purchase agreement, the seller agreed to leave a certain amount of working capital, to be netted against cash consideration, calculated as the difference between cash on hand plus accounts receivable before adjustments allowances and prepaid assets, less accounts payable, accrued liabilities net of adjustments to vacation accruals and deferred revenue, (adjusted for revenue from one distinct customer in the amount of $170,000). The working capital as of June 30, 2012 was as follows:

The deferred costs associated with the term loan are as follows:

These cost will be amortized over the two year term of the loan.

In addition, the remaining success fee of $214,915, on the previous term loan, is accrued until paid.

The allocation of equity transaction is as follows:

The common stock warrants are recorded based on the allocated value of the proceeds, the convertible subordinated note is recorded based on its face value less the difference between the face value and the allocated proceeds, and the preferred shares are recorded based on allocated proceeds less the beneficial conversion feature.

The beneficial conversion feature was determined as follows:

The convertible subordinated note is recorded at its face value, with a discount on the note recorded as the difference between the face value and the allocated proceeds amount.

These costs were allocated between the liability and equity components as follows:

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS

For the Twelve Months Ended January 31, 2012

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS

For the Six Months Ended July 31, 2012